VIDEO: Aflibercept 8 mg shows sustained vision benefits at 96 weeks
Click Here to Manage Email Alerts
In this Healio Video Perspective from the AAO meeting, Diana V. Do, MD, overviews positive 96-week efficacy and safety data from the PHOTON study investigating aflibercept 8 mg in patients with diabetic macular edema.
Patients randomized to aflibercept 8 mg were dosed every 12 or 16 weeks, while patients randomized to aflibercept 2 mg were dosed every 2 months.
“The results showed that aflibercept 8 mg met its primary endpoint, and the visual acuity was noninferior to 2 milligrams of aflibercept at week 48,” she said. “In addition, when we followed these patients for up to 2 years, those vision benefits with aflibercept 8 mg were sustained.”
Collapse
Do D. Aflibercept 8 mg for diabetic macular edema: 96-week results of the PHOTON study. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.
Read more about
Click Here to Manage Email Alerts